

Pseudomonas aeruginosa, Strain MRSN 18803

Catalog No. NR-51591

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (*P. aeruginosa*), strain MRSN 18803 was isolated in 2013 from a human respiratory sample in the United States as part of a global surveillance program. *P. aeruginosa*, strain MRSN 18803 was deposited as multi-locus sequence type (MLST) ST 2132, sensitive to amikacin, cefepime, ceftazidime, gentamicin, imipenem, meropenem and tobramycin, intermediately resistant to aztreonam and piperacillin/tazobactam and resistant to ciprofloxacin and levofloxacin. NR-51591 was produced by inoculation of BEI Resources seed lot 70025089 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70075001

Manufacturing Date: 27MAR2025

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphologies ¹ Motility (wet mount) VITEK® MS (MALDI-TOF)	Gram-negative rods Report results Report results <i>P. aeruginosa</i>	Gram-negative rods Colony Type 1: Irregular, low convex, undulate, smooth and cream Colony Type 2: Circular, low convex, entire, smooth and cream Motile <i>P. aeruginosa</i> (99.9%)
Antibiotic Susceptibility Profile ^{2,3} Amikacin Cefazolin Cefepime Ceftazidime Ciprofloxacin Gentamicin Levofloxacin Meropenem Piperacillin/tazobactam Tobramycin	Sensitive Resistant Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive	Sensitive (4 µg/mL) Resistant (≥ 64 µg/mL) Sensitive (4 µg/mL) Sensitive (4 µg/mL) Sensitive (≤ 0.25 µg/mL) ⁴ Sensitive (2 µg/mL) Sensitive (1 µg/mL) ⁵ Sensitive (0.5 µg/mL) Sensitive (8 µg/mL) ⁶ Sensitive (≤ 1 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1430 base pairs)	≥ 99% sequence identity to <i>P. aeruginosa</i> , strain MRSN 18803 (GenBank: RXVG01000106.1)	99.9% sequence identity to <i>P. aeruginosa</i> , strain MRSN 18803 (GenBank: RXVG01000106.1)
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Two colony types were observed. VITEK® MS (MALDI-TOF) analysis identified cells from both colony types as *P. aeruginosa*.

²Minimum Inhibitory Concentration (MIC); MIC interpretation was determined using VITEK® 2 software version 09.02 combined with the bioMérieux Advanced Expert System™ (AES) software using the interpretation standard CLSI M100-S28 (2018) and the interpretation guideline "Natural Resistance." For more information, please refer to Sanders, C. C., et al. "Potential Impact of the VITEK® 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital." *J. Clin. Microbiol.* 39 (2001): 2379-2385. PubMed: 11427542.

³*P. aeruginosa* and other nonfermentative gram-negative bacteria are intrinsically resistant to penicillin, cephalosporins I, cephalosporin II, cephamycins, clindamycin, daptomycin, fusidic acid, glycopeptides, linezolid, macrolides, quinupristin-dalfopristin, and rifampin. These antibiotics

Certificate of Analysis for NR-51591

were removed from the VITEK® 2 GN81 card and are no longer tested: ampicillin, amoxicillin, amoxicillin/clavulanic acid, cefoxitin, ceftriaxone, cefuroxime, ertapenem, tetracycline, tigecycline, trimethoprim/sulfamethoxazole, chloramphenicol and nitrofurantoin.

⁴*P. aeruginosa*, strain MRSN 18803 was deposited as resistant to ciprofloxacin, but showed a MIC of ≤ 0.25 µg/mL (interpreted as sensitive) for lot 70025088 during QC testing.

⁵*P. aeruginosa*, strain MRSN 18803 was deposited as resistant to levofloxacin, but showed a MIC of 1 µg/mL (interpreted as sensitive) for lot 70025088 during QC testing.

⁶*P. aeruginosa*, strain MRSN 18803 was deposited as intermediately resistant to piperacillin/tazobactam, but showed a MIC of 8 µg/mL (interpreted as sensitive) for lot 70025088 during QC testing.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

12 SEP 2025

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

